The FDA has informed Veloxis of the tentative approval of Envarsus XR (tacrolimus extended relief) for Transplant Rejection. The FDA...
Veloxis Pharmaceuticals A/S announced that Envarsus XR (extended release tacrolimus) was granted Orphan Drug status by the U.S. Food and...
Veloxis Pharmaceuticals has announced that once-daily Envarsus XR (tacrolimus extended-release), for the prevention of organ rejection in adult kidney transplant...
Veloxis Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) to the FDA seeking a new indication for Envarsus XR...
Veloxis Pharmaceuticals announced that the FDA approved a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection...
Veloxis Pharmaceuticals A/S announced FDA approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant...
Veloxis Pharmaceuticals has announced that two-year results of the pivotal Phase III clinical trial, Study 3002, of Envarsus XR (tacrolimus...
Veloxis Pharmaceuticals is announcing the publication of the Phase IIIb Switching STudy of Kidney TRansplant PAtients to LCP-TacrO (STRATO) in...
Veloxis Pharmaceuticals A/S announced the publication of results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release...
Veloxis Pharmaceuticals has filed an action in federal district court for the District of Columbia against the FDA, seeking an...